PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Sinovac Biotech, Beijing, China.\', \'School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China.\', \'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.\', \'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China.\', \'School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China; Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China.\', \'Sinovac Life Sciences, Beijing, China.\', \'Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China. Electronic address: yuliang_zh1@163.com.\', \'Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina.com.\', \'School of Public Health, Fudan University, Key Laboratory of Public Health Safety, Ministry of Education, Shanghai, China; Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China; Department of Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China. Electronic address: yhj@fudan.edu.cn.\', \'Sinovac Biotech, Beijing, China. Electronic address: yinwd@sinovac.comv.\']
?:citedBy
  • -1
?:creator
?:doi
  • S1473-3099(21)00681-210.1016/S1473-3099(21)00681-2
?:doi
?:hasPublicationType
?:journal
  • The Lancet. Infectious diseases
is ?:pmid of
?:pmid
?:pmid
  • 34890537
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34890537>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34890537>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all